ND SB2402

Grants pharmacists in North Dakota independent prescriptive authority for FDA-approved drugs treating conditions including lice, cold sores, motion sickness, hypoglycemia, and—with positive CLIA-waived test results—influenza, strep throat, and COVID-19

Authorizes pharmacists to prescribe specific medical devices (inhalation spacers, nebulizers, diabetes testing supplies, pen needles, epinephrine auto-injectors) and travel medicine drugs after completing accredited continuing education

Permits therapeutic substitution of drugs within the same therapeutic class, excluding antidepressants, antipsychotics, chemotherapy agents, Schedule II controlled substances, biologics, and narrow therapeutic index drugs

Requires pharmacists to maintain patient assessment protocols based on clinical guidelines, notify the patient's primary care provider within 3 business days of prescribing, and document all care provided

Passed Senate 46-0 and House 91-1; becomes effective upon filing with the Secretary of State